Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Tadalafil (LY450190) in Chinese Men With Erectile Dysfunction

Phase 4

Completed

Conditions: Erectile Dysfunction

Interventions: Drug: Tadalafil

First Posted Date: 2014-08-25

Last Posted Date: 2019-09-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 635

Registration Number: NCT02224846

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yinchuan, China

A Study of LY3164530 in Participants With Cancer

Phase 1

Completed

Conditions: Neoplasm Metastasis
Neoplasms

Interventions: Drug: LY3164530

First Posted Date: 2014-08-21

Last Posted Date: 2019-10-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 29

Registration Number: NCT02221882

Locations: 🇺🇸
Pinnacle Oncology Hematology, Scottsdale, Arizona, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
The START Center for Cancer Care, San Antonio, Texas, United States

A Study of LY2409021 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: LY2409021

First Posted Date: 2014-08-15

Last Posted Date: 2018-10-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 16

Registration Number: NCT02217618

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States

A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Peglispro
Drug: Insulin Glargine
Drug: Insulin Lispro

First Posted Date: 2014-07-22

Last Posted Date: 2018-11-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT02197520

Locations: 🇺🇸
Profil Institute for Clinical Research Inc, Chula Vista, California, United States

A Study of LY2623091 in Participants With High Blood Pressure

Phase 2

Completed

Conditions: Primary Hypertension

Interventions: Drug: LY2623091
Drug: Spironolactone
Drug: Placebo
Drug: Tadalafil

First Posted Date: 2014-07-18

Last Posted Date: 2020-06-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 304

Registration Number: NCT02194465

Locations: 🇺🇸
Cor Clinical Research LLC, Oklahoma City, Oklahoma, United States
🇵🇷
Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico
🇺🇸
Mountain View Clinical Research, Inc, Greer, South Carolina, United States

and more 33 locations

A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain

Phase 2

Terminated

Conditions: Osteoarthritis, Knee

Interventions: Other: Placebo- oral
Drug: LY2951742
Other: Placebo - SC
Drug: Celecoxib

First Posted Date: 2014-07-16

Last Posted Date: 2019-09-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 268

Registration Number: NCT02192190

Locations: 🇺🇸
Achieve Clinical Research, LLC, Birmingham, Alabama, United States
🇺🇸
Empire Clinical Research, Upland, California, United States
🇺🇸
Medex Healthcare Research, Inc., New York, New York, United States

and more 34 locations

A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: LY2157299
Drug: Sorafenib
Drug: Placebo

First Posted Date: 2014-06-30

Last Posted Date: 2022-02-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 132

Registration Number: NCT02178358

Locations: 🇹🇭
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangkok, Thailand

Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia

Phase 3

Completed

Conditions: Diabetes Mellitus
Drug-Specific Antibodies
Hypoglycemia

Interventions: Drug: Nasal Glucagon

First Posted Date: 2014-06-24

Last Posted Date: 2019-10-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 129

Registration Number: NCT02171130

Locations: 🇨🇦
Centre de recherche d'endocrinologie Godin & St-Pierre, Sherbrooke, Quebec, Canada
🇺🇸
New England Diabetes and Endocrinology Center (NEDEC), Waltham, Massachusetts, United States
🇨🇦
Winnipeg Clinic, Winnipeg, Manitoba, Canada

and more 6 locations

A Study of Evacetrapib in Participants With Abnormal Cholesterol

Phase 1

Completed

Conditions: Dyslipidemia

Interventions: Drug: Evacetrapib

First Posted Date: 2014-06-20

Last Posted Date: 2018-10-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 101

Registration Number: NCT02168803

Locations: 🇺🇸
Covance, Dallas, Texas, United States
🇺🇸
Covance Clinical Research Inc, Madison, Wisconsin, United States

A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache

Phase 2

Completed

Conditions: Migraine Headache

Interventions: Drug: Placebo
Drug: Galcanezumab

First Posted Date: 2014-06-16

Last Posted Date: 2018-11-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 414

Registration Number: NCT02163993

Locations: 🇺🇸
Clinical Research Advantage, Gilbert, Arizona, United States
🇺🇸
PharmaSite Research Inc, Baltimore, Maryland, United States
🇺🇸
Medical Center for Clinical Research, San Diego, California, United States

and more 35 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy